ArticleMethods in molecular biology (Clifton, N.J.)2026
Method for Assessing Inhibition Kinetics of Autoantibodies Against ADAMTS13 in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy caused by autoantibodies directed against ADAMTS13, a plasma metalloenzyme that cleaves von Willebrand factor (VWF). The autoantibodies are primarily IgG types, and patients typically present with multiple antibodies that are specific to various regions of the protein. Mechanistically, many questions remain regarding exactly how these antibodies modulate ADAMTS13 to lead to the inhibition of its activity. Investigating enzyme kinetics and how the presence of autoantibodies affects these parameters can reveal important insights into the mechanism(s) underlying the antibody-mediated inhibition of ADAMTS13. As the antibodies are central to the pathology of iTTP, gaining a deeper understanding of their effects may lead to the development of targeted therapeutic agents to treat the disease that could potentially be more effective for these patients. Here, we describe a way to analyze the inhibitory kinetics of autoantibodies in the context of iTTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.